ORSERDU (elacestrant)

About Stemline Therapeutics

Stemline Therapeutics is a New York-based oncology company, founded in 2003 and now a subsidiary of the Italian Menarini Group. The company has achieved commercial success with its first-in-class therapy, ELZONRIS, for the rare and aggressive cancer BPDCN, and has expanded its portfolio with the acquisition of ORSERDU for ER+/HER2- metastatic breast cancer. Stemline operates as a fully integrated commercial entity within Menarini, leveraging its parent company's global infrastructure to develop and market targeted oncology therapies. Its strategy involves expanding the labels of its approved drugs into broader indications while advancing its pipeline.

Therapeutic Areas